Protocol

Computational Toxicology

Volume 929 of the series Methods in Molecular Biology pp 439-499

Date:

Physiologically Based Pharmacokinetic/Toxicokinetic Modeling

  • Jerry L. CampbellJr.Affiliated withThe Hamner Institutes for Health Sciences Email author 
  • , Rebecca A. ClewellAffiliated withThe Hamner Institutes for Health Sciences
  • , P. Robinan GentryAffiliated withEnviron International Corporation
  • , Melvin E. AndersenAffiliated withThe Hamner Institutes for Health Sciences
  • , Harvey J. ClewellIIIAffiliated withThe Hamner Institutes for Health Sciences

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Physiologically based pharmacokinetic (PBPK) models differ from conventional compartmental pharmacokinetic models in that they are based to a large extent on the actual physiology of the organism. The application of pharmacokinetics to toxicology or risk assessment requires that the toxic effects in a particular tissue are related in some way to the concentration time course of an active form of the substance in that tissue. The motivation for applying pharmacokinetics is the expectation that the observed effects of a chemical will be more simply and directly related to a measure of target tissue exposure than to a measure of administered dose. The goal of this work is to provide the reader with an understanding of PBPK modeling and its utility as well as the procedures used in the development and implementation of a model to chemical safety assessment using the styrene PBPK model as an example.

Key words

PBPK Styrene Pharmacokinetics